Gilead Sciences Newswire

Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 2,493 in Gilead Sciences

  1. Gilead Sciences Inc. (GILD) Stake Decreased by Babson Capital Management LLCRead the original story w/Photo

    9 hrs ago | Daily Political

    Babson Capital Management LLC cut its stake in Gilead Sciences Inc. by 1.0% during the first quarter, Holdings Channel reports. The fund owned 199,722 shares of the biopharmaceutical company's stock after selling 2,100 shares during the period.

    Comment?

  2. Traders Buy Shares of Gilead Sciences Inc. (GILD) on WeaknessRead the original story w/Photo

    11 hrs ago | Daily Political

    Investors purchased shares of Gilead Sciences Inc. on weakness during trading on Friday. $357.33 million flowed into the stock on the tick-up and $281.22 million flowed out of the stock on the tick-down, for a money net flow of $76.11 million into the stock.

    Comment?

  3. Research Analysts Set Expectations for Gilead Sciences Inc.'s Q3 2016 EarningsRead the original story w/Photo

    15 hrs ago | Daily Political

    Gilead Sciences Inc. - Stock analysts at Jefferies Group issued their Q3 2016 earnings per share estimates for shares of Gilead Sciences in a research note issued on Monday. Jefferies Group analyst B. Abrahams anticipates that the brokerage will post earnings per share of $3.03 for the quarter.

    Comment?

  4. William Blair Weighs in on Gilead Sciences Inc.'s Q3 2016 EarningsRead the original story w/Photo

    17 hrs ago | Daily Political

    Gilead Sciences Inc. - Research analysts at William Blair issued their Q3 2016 earnings per share estimates for shares of Gilead Sciences in a report issued on Tuesday. William Blair analyst J. Sonnier forecasts that the firm will earn $2.79 per share for the quarter.

    Comment?

  5. 3,152 Shares in Gilead Sciences Inc. (GILD) Acquired by Highland Private Wealth ManagementRead the original story w/Photo

    Yesterday | Daily Political

    Highland Private Wealth Management purchased a new stake in shares of Gilead Sciences Inc. during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission . The institutional investor purchased 3,152 shares of the biopharmaceutical company's stock, valued at approximately $289,000.

    Comment?

  6. Gilead Sciences Inc. (GILD) Receives Overweight Rating from Barclays PLCRead the original story w/Photo

    Friday | Daily Political

    A number of other equities research analysts have also commented on GILD. Credit Suisse Group AG restated an outperform rating and set a $120.00 price target on shares of Gilead Sciences in a research report on Thursday, April 28th.

    Comment?

  7. venBio Select Advisor LLC Takes Position in Gilead Sciences Inc.Read the original story w/Photo

    Friday | Daily Political

    The fund bought 175,400 shares of the biopharmaceutical company's stock, valued at approximately $16,112,000. Gilead Sciences comprises 5.6% of venBio Select Advisor LLC's holdings, making the stock its 5th largest position.

    Comment?

  8. Gilead Sciences Inc. (GILD) Position Maintained by Kelly Lawrence W & Associates Inc. CARead the original story w/Photo

    Friday | Daily Political

    Kelly Lawrence W & Associates Inc. CA continued to hold its stake in shares of Gilead Sciences Inc. during the first quarter, Holdings Channel reports. The firm owned 39,000 shares of the biopharmaceutical company's stock at the end of the first quarter.

    Comment?

  9. $1 million gift to BioFrontiers Institute to aid CU grad studentsRead the original story

    Friday | The Boulder County Business Report

    ... of the BioFrontiers IQ Biology PhD Certificate program. Milligan is president and chief of California-based Gilead Sciences Inc. that has operations in North America, Europe, Asia and Australia. The biopharma company is focused on discovering, ...

    Comment?

  10. Gilead (GILD) Stock Down on Q3 Outlook, Argus DowngradesRead the original story w/Photo

    Friday | TheStreet.com

    Shares of Gilead Sciences are falling 2.08% to $79.55 after the company reported disappointing guidance for the 2016 third quarter following Monday's market close. Gilead revised its guidance for 2016 total product sales to a range of $29.5 billion to $30.5 billion, down from previous estimates of $30 billion to $31 billion.

    Comment?

  11. Merck beats 2Q profit forecasts, lowers guidanceRead the original story w/Photo

    Friday | Houston Chronicle

    ... January, posted sales of just $112 million. Merck is selling Zepatier at a big discount to entrenched leader Gilead Sciences Inc. 's Harvoni and Sovaldi, which are bringing in billions each quarter, to try to grab market share. Keytruda, Merck's ...

    Comment?

  12. Merck revenue boosted by cancer, hepatitis drugsRead the original story w/Photo

    Friday | MarketWatch

    ... C, the latest entrant in a booming market for drugs for the viral infection -- a market now dominated by Gilead Sciences Inc. Zepatier had sales of $112 million, compared with $50 million in the first quarter. Nasonex sales fell 53% in the first ...

    Comment?

  13. Traders Sell Shares of Gilead Sciences Inc. (GILD) on Strength After Analyst DowngradeRead the original story w/Photo

    Friday | Daily Political

    Investors sold shares of Gilead Sciences Inc. on strength during trading on Wednesday after Zacks Investment Research downgraded the stock from a buy rating to a hold rating. $189.38 million flowed into the stock on the tick-up and $251.19 million flowed out of the stock on the tick-down, for a money net flow of $61.81 million out of the stock.

    Comment?

  14. Brokers Set Expectations for Gilead Sciences Inc.'s Q3 2016 EarningsRead the original story w/Photo

    Friday | Daily Political

    Gilead Sciences Inc. - Equities research analysts at Leerink Swann decreased their Q3 2016 earnings per share estimates for Gilead Sciences in a research report issued to clients and investors on Tuesday. Leerink Swann analyst G. Porges now forecasts that the brokerage will earn $2.94 per share for the quarter, down from their prior forecast of $3.16.

    Comment?

  15. RBC Capital Markets Reiterates Outperform Rating for Gilead Sciences Inc.Read the original story w/Photo

    Thursday Jul 28 | Daily Political

    ... recently made changes to their positions in GILD. Joel Isaacson & Co. LLC increased its stake in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company's stock valued ...

    Comment?

  16. Royal Bank Of Canada Lowers Gilead Sciences Inc. (GILD) Price Target to $105.00Read the original story w/Photo

    Thursday Jul 28 | Daily Political

    ... current price. Several other research firms have also recently weighed in on GILD. Vetr cut shares of Gilead Sciences from a "buy" rating to a "hold" rating and set a $105.42 price objective for the company. in a research report on Thursday, April ...

    Comment?

  17. Brokers Offer Predictions for Gilead Sciences Inc.'s Q3 2016 EarningsRead the original story w/Photo

    Thursday Jul 28 | AmericanBankingNews.com

    Gilead Sciences Inc. - Jefferies Group issued their Q3 2016 earnings per share estimates for Gilead Sciences in a report released on Monday. Jefferies Group analyst B. Abrahams forecasts that the firm will post earnings of $3.03 per share for the quarter.

    Comment?

  18. Leerink Swann Weighs in on Gilead Sciences Inc.'s Q3 2016 EarningsRead the original story w/Photo

    Thursday Jul 28 | AmericanBankingNews.com

    Gilead Sciences Inc. - Leerink Swann lowered their Q3 2016 EPS estimates for shares of Gilead Sciences in a research note issued on Tuesday. Leerink Swann analyst G. Porges now forecasts that the firm will post earnings of $2.94 per share for the quarter, down from their prior estimate of $3.16.

    Comment?

  19. Is The End Near For Gilead Sciences?Read the original story w/Photo

    Thursday Jul 28 | Seeking Alpha

    In the first of a two-part series, I will examine the recent report with part two updating my fair value on Gilead Sciences. Gilead Sciences recent less than stellar earnings report served as the catalyst for a fresh leg down in the share price.

    Comment?

  20. Gilead Sciences Inc. (GILD) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Thursday Jul 28 | AmericanBankingNews.com

    ... As per management, we may see activities on the merger & acquisitions front at the company going ahead." Gilead Sciences (NASDAQ:GILD) opened at 81.015 on Thursday. The company has a 50-day moving average price of $84.38 and a 200 day moving average ...

    Comment?